BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32843101)

  • 1. Fabry disease screening in high-risk populations in Japan: a nationwide study.
    Yoshida S; Kido J; Sawada T; Momosaki K; Sugawara K; Matsumoto S; Endo F; Nakamura K
    Orphanet J Rare Dis; 2020 Aug; 15(1):220. PubMed ID: 32843101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
    Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
    J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.
    Sawada T; Kido J; Sugawara K; Matsumoto S; Takada F; Tsuboi K; Ohtake A; Endo F; Nakamura K
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1502. PubMed ID: 33016649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
    Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
    Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study.
    Inoue T; Hattori K; Ihara K; Ishii A; Nakamura K; Hirose S
    J Hum Genet; 2013 Aug; 58(8):548-52. PubMed ID: 23677059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance.
    van der Tol L; Smid BE; Poorthuis BJ; Biegstraaten M; Deprez RH; Linthorst GE; Hollak CE
    J Med Genet; 2014 Jan; 51(1):1-9. PubMed ID: 23922385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide screening for Fabry disease in unselected stroke patients.
    Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
    PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males.
    Oliveira JP; Nowak A; Barbey F; Torres M; Nunes JP; Teixeira-E-Costa F; Carvalho F; Sampaio S; Tavares I; Pereira O; Soares AL; Carmona C; Cardoso MT; Jurca-Simina IE; Spada M; Ferreira S; Germain DP
    Eur J Med Genet; 2020 Feb; 63(2):103703. PubMed ID: 31200018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.
    Ferreira S; Ortiz A; Germain DP; Viana-Baptista M; Caldeira-Gomes A; Camprecios M; Fenollar-Cortés M; Gallegos-Villalobos Á; Garcia D; García-Robles JA; Egido J; Gutiérrez-Rivas E; Herrero JA; Mas S; Oancea R; Péres P; Salazar-Martín LM; Solera-Garcia J; Alves H; Garman SC; Oliveira JP
    Mol Genet Metab; 2015 Feb; 114(2):248-58. PubMed ID: 25468652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
    Duro G; Zizzo C; Cammarata G; Burlina A; Burlina A; Polo G; Scalia S; Oliveri R; Sciarrino S; Francofonte D; Alessandro R; Pisani A; Palladino G; Napoletano R; Tenuta M; Masarone D; Limongelli G; Riccio E; Frustaci A; Chimenti C; Ferri C; Pieruzzi F; Pieroni M; Spada M; Castana C; Caserta M; Monte I; Rodolico MS; Feriozzi S; Battaglia Y; Amico L; Losi MA; Autore C; Lombardi M; Zoccali C; Testa A; Postorino M; Mignani R; Zachara E; Giordano A; Colomba P
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review.
    Sawada T; Kido J; Sugawara K; Nakamura K
    Diagnostics (Basel); 2021 Sep; 11(10):. PubMed ID: 34679477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing.
    Delarosa-Rodríguez R; Santotoribio JD; Paula HA; González-Meneses A; García-Morillo S; Jiménez-Arriscado P; Guerrero JM; Macher HC
    Clin Genet; 2021 Jun; 99(6):761-771. PubMed ID: 33527381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
    Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
    Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of the GLA gene in Mexican families with Fabry disease.
    Gutiérrez-Amavizca BE; Gal A; Ortíz-Orozco R; Orth U; Prado Montes De Oca E; Gutiérrez-Amavizca JP; Figuera LE
    J Genet; 2017 Mar; 96(1):161-164. PubMed ID: 28360401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
    Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
    Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
    PLoS One; ; . PubMed ID: 32987398
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.